

Une approche stochastique à la modélisation de l'immunothérapie contre le cancer

Loren Coquille

-

Travail en collaboration avec

Martina Baar, Anton Bovier, Hannah Mayer (IAM Bonn)

Michael Hölzel, Meri Rogava, Thomas Tüting (UniKlinik Bonn)

Institut Fourier – Grenoble

Séminaire commun IF/LJK - 17 septembre 2015

Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion

Plan



- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion

Experiment on melanoma (UniKlinik Bonn)

Injection of T-cells able to kill a specific type of melanoma.

The treatment induces an **inflammation**, to which the melanoma react by changing their phenotype (markers disappear on their surface, "**switch**").


The T-cells cannot kill them any more, the tumor continues to grow.



Without therapy : exponential growth of the tumor.

With therapy : relapse after 140 days.

With therapy and restimulation : late relapse.



Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion

Individual-based model

- **Cancer cells (melanoma):** each cell is characterized by a genotype and a phenotype. Each can **reproduce**, **die**, **mutate** (reproduction with genotypic change) or **switch** (phenotypic change, without reproduction) at prescribed rates.
- **Immune cells (T-cells):** Each cell can **reproduce**, **die**, or **kill** a cancer cell of prescribed type (which produces a chemical messenger) at prescribed rates.
- **Chemical messenger (TNF- α):** Each particle can **die** at a prescribed rate. Its presence influences the ability of a fixed type of cancer cell to switch.

Trait space and measure :

$$\mathcal{X} = \mathcal{G} \times \mathcal{P} \sqcup \mathcal{Z} \sqcup \mathcal{W} = \{g_1, \dots, g_{|\mathcal{G}|}\} \times \{p_1, \dots, p_{|\mathcal{P}|}\} \sqcup \{z_1, \dots, z_{|\mathcal{Z}|}\} \sqcup w$$

$$n = (n_{(g_1, p_1)}, \dots, n_{(g_{|\mathcal{G}|}, p_{|\mathcal{P}|})}, n_{z_1}, \dots, n_{z_{|\mathcal{Z}|}}, n_w)$$

Example for 2 types of melanoma and 1 type of T-cell

The stochastic model converges, in the limit of large populations, towards the solution this dynamical system with **logistic**, **predator-prey**, **switch**:

$$\begin{cases} \dot{n}_x &= n_x \left(b_x - d_x - c_{xx} \cdot n_x - c_{xy} \cdot n_y \right) + s \cdot n_y - s_w \cdot n_w n_x - t_{xz} \cdot n_{z_x} n_x \\ \dot{n}_y &= n_y \left(b_y - d_y - c_{yy} \cdot n_y - c_{yx} \cdot n_x \right) - s \cdot n_y + s_w \cdot n_w n_x \\ \dot{n}_{z_x} &= - d_{z_x} \cdot n_{z_x} + b_{z_x} \cdot n_{z_x} n_x \\ \dot{n}_w &= - d_w \cdot n_w + l_x \cdot t_{xz} \cdot n_x n_{z_x} \end{cases}$$

Event	Rates for x	Rates for y	for z	for w
(Re)production	b_x	b_y	$b_{z_x} n_x$	
Natural death	$d_x + c_{xx} n_x + c_{xy} n_y$	$d_y + c_{yy} n_x + c_{yx} n_y$	d_{z_x}	d_w
Therapy death	$t_{xz} n_{z_x}$	0		
Switch	$s_w n_w$	s		

Deterministically, a number l_w of TNF- α particles are produced when z_x kills x .

State of the art for the BPDFL model

In general \mathcal{X} continuous. Measure $\nu_t = \sum_{i=1}^{N_t} \delta_{x_i}$.

Markov process on the space of positive measures.

Event	Rate
Clonal reproduction	$(1 - p(x)) \cdot b(x)$
Reproduction with mutation	$m(x, dy) \cdot p(x) \cdot b(x)$
Death	$d(x) + \int_{\mathcal{X}} c(x, y) \nu(dy)$

State of the art for the BPDFL model

In general \mathcal{X} continuous. Measure $\nu_t = \frac{1}{K} \sum_{i=1}^{N_t} \delta_{x_i}$.
 Markov process on the space of positive measures.

Event	Rate
Clonal reproduction	$(1 - \mu p(x)) \cdot b(x)$
Reproduction with mutation	$m(x, dy) \cdot \mu p(x) \cdot b(x)$
Death	$d(x) + \int_{\mathcal{X}} \frac{c(x,y)}{K} \nu(dy)$

Limit of large populations and rare mutations

$$K \rightarrow \infty$$

$$\mu \rightarrow 0$$

Scalings and time scales

- $K \rightarrow \infty$, μ fixed, $T < \infty$:
Law of large numbers, deterministic limit
[Fournier, Méléard, 2004]
- $K \rightarrow \infty$, $\mu \rightarrow 0$, $T < \infty$:
Law of large numbers, deterministic limit without mutations.
- $K \rightarrow \infty$, $\mu \rightarrow 0$, $T \sim \log(1/\mu)$:
Deterministic jump process
[Bovier, Wang, 2012]
- $(K, \mu) \rightarrow (\infty, 0)$ t.q. $\frac{1}{\mu K} \gg \log K$, $T \sim \frac{1}{\mu K}$:
Random jump process
[Champagnat, Méléard, 2009, 2010]
Trait Substitution Sequence
Polymorphic Evolution Sequence

Scalings and time scales


- $K \rightarrow \infty$, μ fixed, $T < \infty$:
Law of large numbers, deterministic limit
[Fournier, Méléard, 2004]
limit dynamical systems (with switch) are not classified
- $K \rightarrow \infty$, $\mu \rightarrow 0$, $T < \infty$:
Law of large numbers, deterministic limit without mutations.
- $K \rightarrow \infty$, $\mu \rightarrow 0$, $T \sim \log(1/\mu)$:
Deterministic jump process
[Bovier, Wang, 2012]
- $(K, \mu) \rightarrow (\infty, 0)$ t.q. $\frac{1}{\mu K} \gg \log K$, $T \sim \frac{1}{\mu K}$:
Random jump process
[Champagnat, Méléard, 2009, 2010]
Trait Substitution Sequence
Polymorphic Evolution Sequence

Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations**
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion


Solution of the deterministic system

Legend : Melanoma x , melanoma y , T-cells, TNF- α




3 fixed points


With reasonable parameters we have :




P_{xyz} is stable.


P_{xy0} is stable on the invariant sub-space $\{n_{z_x} = 0\}$.

Relapse towards P_{xyz} , ($K = 200$)

Relapse towards P_{xy0} due to the death of z_x 

Adjustment of parameters : data



Adjustment of parameters : simulations ($K = 10^5$)

Therapy with 1 types of T-cells

$$\begin{cases} \dot{n}_x &= n_x \left(b_x - d_x - c_{xx} \cdot n_x - c_{xy} \cdot n_y \right) - t_{xz} \cdot n_{z_x} n_x + s \cdot n_y - s_w \cdot n_w n_x \\ \dot{n}_y &= n_y \left(b_y - d_y - c_{yy} \cdot n_y - c_{yx} \cdot n_x \right) - s \cdot n_y + s_w \cdot n_w n_x \\ \dot{n}_{z_x} &= - d_{z_x} \cdot n_{z_x} + b_{z_x} \cdot n_{z_x} n_x \\ \dot{n}_w &= - d_w \cdot n_w + l_x \cdot t_{xz} \cdot n_x n_{z_x} \end{cases}$$

Event	Rates for x	Rates for y
Reproduction	b_x	b_y
Natural death	$d_x + c_{xx} n_x + c_{xy} n_y$	$d_y + c_{yy} n_x + c_{yx} n_y$
Death due to therapy	$t_{xz} n_{z_x}$	0
Switch	$s_w n_w$	s


Therapy with 2 types of T-cells

$$\begin{cases} \dot{n}_x &= n_x \left(b_x - d_x - c_{xx} \cdot n_x - c_{xy} \cdot n_y \right) - t_{xz} \cdot n_{z_x} n_x + s \cdot n_y - s_w \cdot n_w n_x \\ \dot{n}_y &= n_y \left(b_y - d_y - c_{yy} \cdot n_y - c_{yx} \cdot n_x \right) - t_{yz} \cdot n_{z_y} n_y - s \cdot n_y + s_w \cdot n_w n_x \\ \dot{n}_{z_x} &= -d_{z_x} \cdot n_{z_x} + b_{z_x} \cdot n_{z_x} n_x \\ \dot{n}_{z_y} &= -d_{z_y} \cdot n_{z_y} + b_{z_y} \cdot n_{z_y} n_y \\ \dot{n}_w &= -d_w \cdot n_w + l_x \cdot t_{xz} \cdot n_x n_{z_x} + l_y \cdot t_{yz} \cdot n_y n_{z_y} \end{cases}$$


Event	Rates for x	Rates for y
Reproduction	b_x	b_y
Natural death	$d_x + c_{xx} n_x + c_{xy} n_y$	$d_y + c_{yy} n_x + c_{yx} n_y$
Death due to therapy	$t_{xz} n_{z_x}$	$t_{yz} n_{z_y}$
Switch	$s_w n_w$	s

Solution of the deterministic limit

Legend : Melanoma x , melanoma y , T-cell z_x , T-cell z_y , TNF- α



5 fixed points




$P_{xyz_xz_y}$ is stable.

P_{xyz_x0} is stable in the invariant subspace $\{n_{z_y} = 0\}$


P_{xy0z_y} is stable in the invariant subspace $\{n_{z_x} = 0\}$

P_{xy00} is stable in the invariant subspace $\{n_{z_x} = 0\} \cap \{n_{z_y} = 0\}$


Metastable transitions between several possible relapses




Metastable transitions between several possible relapses





Metastable transitions between several possible relapses





Stochastic system close to the deterministic system



Relapse towards P_{xyz_0} caused by the death of z_y 

Relapse towards P_{xy0z_y} caused by the death of z_x 

Relapse towards P_{xy00} caused by the death of z_x and z_y 

Cure ! ($P=0000$)

Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy**
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion

Example for 2 types of melanoma and 1 type of T-cell

BPDL + therapy with usual competition

Event	Rates for x
Clonal reproduction	$(1 - \mu)b_x$
Mutation towards y	μb_x
Natural death	$d_x + c_{xx}n_x + c_{xy}n_y$
Death due to therapy	$t_{zx}n_z$

Example for 2 types of melanoma and 1 type of T-cell

BPDL + therapy with birth-reducing competition

Event	Rates for x
Clonal reproduction	$(1 - \mu) [b_x - c_{xx}n_x - c_{xy}n_y]_+$
Mutation towards y	$\mu [b_x - c_{xx}n_x - c_{xy}n_y]_+$
Natural death	$d_x + [b_x - c_{xx}n_x - c_{xy}n_y]_-$
Death due to therapy	$t_{zx}n_z$

Example for 2 types of melanoma and 1 type of T-cell

BPDL + therapy with birth-reducing competition

Event	Rates for y
Clonal reproduction	$[b_y - c_{yy}n_y - c_{yx}n_x]_+$
Mutation towards x	0
Natural death	$d_y + [b_y - c_{yy}n_y - c_{yx}n_x]_-$
Death due to therapy	0

Event	Rates for z
Reproduction	$b_{zx}n_x$
Death	d_z

No switch \Rightarrow The chemical messenger (TNF- α) has a trivial role : $\dot{n}_w = 0$

Limiting deterministic system

When $(K, \mu) \rightarrow (\infty, 0)$ such that

$$\mu \cdot K \rightarrow \alpha > 0$$

then μ disappears from the deterministic system on the time scale $T < \infty$ (mutant appear after a time $O(1/\mu K) = O(1)$ but need $O(\log(K)) \rightarrow \infty$ to become macroscopic).

$$\begin{cases} \dot{n}_x &= n_x \left(b_x - d_x - c_{xx} \cdot n_x - c_{xy} \cdot n_y \right) - t_{xz} \cdot n_{z_x} n_x \\ \dot{n}_y &= n_y \left(b_y - d_y - c_{yy} \cdot n_y - c_{yx} \cdot n_x \right) \\ \dot{n}_{z_x} &= -d_{z_x} \cdot n_{z_x} + b_{z_x} \cdot n_{z_x} n_x \end{cases}$$


The deterministic system doesn't "see" the difference between death enhancing and birth-reducing competition.

With *birth-reducing* competition

Let $n(0) = (n_x(0), 0, 0)$,

then the initial **mutation rate** is **quadratic** in the population n_x :

$$m(n_x) := \mu [b_x - c_{xx}n_x]_+ n_x$$





$\bar{n}_x := \frac{b_x - d_x}{c_{xx}}$ is the equilibrium of the initial x population.

A **smaller population** can have a **higher mutation rate**.


Note $m(n_x) = O(\mu K) = O(1)$.

Without treatment and $n_x(0) \simeq \bar{n}_x$



Without treatment and $n_x(0)$ small

With treatment




Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence**
- 6 Conclusion

Two time scales

Rares mutations in $\mathcal{G} : (K, \mu) \rightarrow (\infty, 0)$ s.t. $\mu \ll 1/K \log K$

Fast switches in $\mathcal{P} : \forall p, p' \in \mathcal{P} \quad s_{(g,p),(g,p')} = O(1)$




No therapy (only melanoma)

Consider an initial population of genotype g (associated with ℓ different phenotypes p_1, \dots, p_ℓ) which is able to mutate at rate μ to another genotype g' , associated with k different phenotypes p'_1, \dots, p'_k .

Consider as initial condition $n(0) = (n_{(g,p_1)}(0), \dots, n_{(g,p_\ell)}(0))$ a stable fixed point, \bar{n} , of the following system:

$$\dot{n}_{(g,p_i)} = n_{(g,p_i)} \left(b_i - d_i - \sum_{j=1}^{\ell} c_{ij} n_{(g,p_j)} - \sum_{j=1}^{\ell} s_{ij} \right) + \sum_{j=1}^{\ell} s_{ji} n_{(g,p_j)}.$$

Study of one step (example with $\ell = 1, k = 2$)

←1→ ←2→ ←3→

Phase 1 : approximation with supercritical multi-type branching, $O(\log(K))$

Phase 2 : approximation with the deterministic system, $O(1)$

Phase 3 : approximation with subcritical multi-type branching, $O(\log(K))$

Invasion fitness ?

For the BPDFL model (without switches) :


$$f(x, M) = b_x - d_x - \sum_{y \in M} c_{xy} \bar{n}_y.$$

is the growth rate of a single individual with trait $x \notin M$ in the presence of the equilibrium population \bar{n} on M .

- $f(x, M) > 0$: positive probability for the mutant (uniformly in K) to **grow** to a population of size $O(K)$;
- $f(x, M) < 0$: the mutant population **dies out** with probability tending to one (as $K \rightarrow \infty$) before this happens.

We need to generalize this notion to the case when fast phenotypic switches are present.

Phase 1



As long as

- $n_{(g,p_i)} \geq \bar{n}_{(g,p_i)} - \varepsilon \quad \forall i = 1, \dots, \ell$
- $\sum_{i=1}^k n_{(g',p'_i)} \leq \varepsilon K$

the mutant population $(g', p'_1), \dots, (g', p'_k)$ is well approximated by a k -type **branching process** with rates:

$$\left. \begin{array}{ll} p'_i \rightarrow p'_i p'_i & \text{with rate } b'_i \\ p'_i \rightarrow \emptyset & \text{with rate } d'_i + \sum_{l=1}^{\ell} c_{il} \bar{n}_l \\ p'_i \rightarrow p'_j & \text{with rate } s'_{ij} \end{array} \right\}$$

Multi-type branching processes have been analysed by Kesten/Stigum and Atreya/Ney. Their behavior are classified in terms of the matrix A , given by

$$A = \begin{pmatrix} f_1 & s'_{12} & \dots & s'_{1k} \\ s'_{21} & f_2 & & \vdots \\ \vdots & & \ddots & \\ s'_{k1} & \dots & & f_k \end{pmatrix}$$


where

$$f_i := b'_i - d'_i - \sum_{l=1}^{\ell} c_{il} \cdot \bar{n}_l - \sum_{j=1}^k s'_{ij}.$$

The multi-type process is super-critical, if and only if the largest eigenvalue, $\lambda_1 = \lambda_1(A) > 0$. It is thus the appropriate generalization of the invasion fitness:

$$F(g', g) := \lambda_1(A).$$

Example : Resonance



$$\begin{aligned}
 s_{12} &= s_{21} = 2 \\
 f_1 &= f_2 = -1 \\
 F(g', g) &= \lambda_1 = 1 \\
 \tilde{F}(g, g') &= -1
 \end{aligned}$$

Plan

- 1 Biological motivations
- 2 Adaptative dynamics
 - The model
 - State of the art
- 3 Only switches : Relapse caused by stochastic fluctuations
 - Therapy with 1 type of T-cell
 - Biological parameters
 - Therapy with 2 types of T-cells
- 4 Only mutations : Early mutation induced by the therapy
- 5 Mutations and switches : Polymorphic Evolution Sequence
- 6 Conclusion

Still a lot to understand...

Biologically :

- measure precise parameters appearing in the model
- check predictions (e.g. therapy with 2 types of T-cells)
- etc.

Mathematically :

- How do the transition probabilities between different relapses scale with K ?
- What happens if the deterministic system has limit cycles ?
- How does the birth-reducing competition affect the mutation probability in presence of treatment?
- etc.

Merci !